What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?van der Geest, K. S. M., Sandovici, M., van Sleen, Y., Sanders, J-S., Bos, N. A., Abdulahad, W. H., Stegeman, C. A., Heeringa, P., Rutgers, A., Kallenberg, C. G. M., Boots, A. M. H. & Brouwer, E., Sep-2018, In : Arthritis & Rheumatology. 70, 9, p. 1366-1376 11 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.
|Number of pages||11|
|Journal||Arthritis & Rheumatology|
|Publication status||Published - Sep-2018|
- PLACEBO-CONTROLLED TRIAL, POPULATION-BASED COHORT, VARICELLA-ZOSTER-VIRUS, ERYTHROCYTE SEDIMENTATION-RATE, UNINFLAMED TEMPORAL ARTERY, ENDOTHELIAL GROWTH-FACTOR, LARGE-VESSEL VASCULITIS, PERMANENT VISUAL-LOSS, POLYMYALGIA-RHEUMATICA, ISCHEMIC COMPLICATIONS